IE
CCCC icon

Israel Englander’s C4 Therapeutics CCCC Stock Holding History

Israel Englander’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Sell
215,386
-1,177,956
-85% -$4.03M ﹤0.01% 4309
2026
Q1 		$3.66M Buy
1,393,342
+204,373
+17% +$481K ﹤0.01% 3284
2025
Q4 		$2.27M Sell
1,188,969
-745,256
-39% -$1.77M ﹤0.01% 3825
2025
Q3 		$4.29M Buy
1,934,225
+832,883
+76% +$2M ﹤0.01% 3296
2025
Q2 		$1.57M Buy
1,101,342
+1,035,445
+1,571% +$1.51M ﹤0.01% 4080
2025
Q1 		$105K Sell
65,897
-294,228
-82% -$878K ﹤0.01% 5428
2024
Q4 		$1.3M Buy
360,125
+338,277
+1,548% +$1.68M ﹤0.01% 3993
2024
Q3 		$125K Sell
21,848
-487,558
-96% -$2.93M ﹤0.01% 5544
2024
Q2 		$2.35M Sell
509,406
-65,725
-11% -$392K ﹤0.01% 3396
2024
Q1 		$4.7M Sell
575,131
-157,014
-21% -$1.22M ﹤0.01% 2923
2023
Q4 		$4.14M Sell
732,145
-435,227
-37% -$992K ﹤0.01% 2945
2023
Q3 		$2.17M Sell
1,167,372
-968,225
-45% -$2.95M ﹤0.01% 3476
2023
Q2 		$5.87M Buy
2,135,597
+1,982,041
+1,291% +$6.37M ﹤0.01% 2521
2023
Q1 		$482K Buy
+153,556
New +$904K ﹤0.01% 4627
2022
Q3 		– Sell
-425,647
Closed -$3.21M – 7094
2022
Q2 		$3.21M Sell
425,647
-565,294
-57% -$4.97M ﹤0.01% 3230
2022
Q1 		$24M Buy
990,941
+237,550
+32% +$5.77M 0.01% 1202
2021
Q4 		$24.3M Buy
753,391
+465,818
+162% +$18.4M 0.01% 1275
2021
Q3 		$12.8M Sell
287,573
-96,975
-25% -$4.15M 0.01% 1759
2021
Q2 		$14.6M Buy
384,548
+205,480
+115% +$7.36M 0.01% 1503
2021
Q1 		$6.62M Sell
179,068
-375,500
-68% -$14.9M ﹤0.01% 2272
2020
Q4 		$18.4M Buy
+554,568
New +$16.1M 0.01% 1143

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Israel Englander's CCCC Position: Q2 2026 in Review

Israel Englander reduced its C4 Therapeutics (CCCC) stake by 85% in Q2 2026, selling an estimated $4.03M and leaving 215,386 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #4309.

Israel Englander first reported a position in CCCC in Q4 2020 and has held it in 21 quarters since. The position peaked at $24.3M in Q4 2021. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Israel Englander held 215,386 shares of C4 Therapeutics worth $1.01M as of Q2 2026.
  • Israel Englander sold 1,177,956 C4 Therapeutics shares in Q2 2026, an estimated $4.03M.
  • C4 Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4309 holding.
  • Israel Englander first reported a position in C4 Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Israel Englander's C4 Therapeutics position peaked at $24.3M in Q4 2021.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.